Skip to Main Content
Skip Nav Destination

FDA approves severe eosinophilic asthma treatment for children ages 6-11 :

September 13, 2019

The U.S. Food and Drug Administration (FDA) has approved the use of mepolizumab to treat severe asthma in children as young as 6 years.

Mepolizumab (GlaxoSmithKline’s Nucala) is an add-on maintenance treatment to help decrease airway inflammation in patients with severe eosinophilic asthma, which afflicts about 9,000 children in the U.S.

The treatment has been approved as a 40-milligram (mg) dose injection for children ages 6-11 and is the only biologic approved for this age group to treat severe asthma. In 2015, it was licensed for patients 12 and older as a 100-mg dose. Trials have found it its safety profile to be similar to that of older children.

Full prescribing information is available at

Close Modal

or Create an Account

Close Modal
Close Modal